Portfolio

François TORCHE, CEO

"A strong corporate structure is a key asset to improve the scalability of the business. Theodorus helped us improve our governance and our decision-making process in order to focus on actions that create long term value and increase the chances of a successful EXIT."

Thomas LIENARD, CEO

"Theodorus helped Bone Therapeutics as a lead investor from its seed funding until its IPO. Its managers gave us a strong support during our various funding rounds."

Filter on

Theodorus I Theodorus II Theodorus III Theodorus IV

Investment Portfolio

17 companies

High tech

Exit

Sector: High tech

Employees: 47

European leader in Space Thermal control systems based upon 2-Phase Systems with more than 30 years of in orbit heritage. It has been acquired by Airbus Defence and Space in 2017.

Visit Website

High tech

Exit

Sector: High tech

Employees: 40

Designs, develops and manufactures optical and metrology systems and sub-systems for space, industry and ophthalmology. It has been acquired through an MBO in 2008.

Visit website

Biotech

Exit

Sector: Biotech

Employees: 130

Dynamic and global Contract Development and Manufacturing Organization for cell therapy companies. It has entered a share deal with Orgenesis in 2015.

Visit website

Medtech

Exit

Sector: Medtech

Employees: 4

Medical device company dedicated to the development of innovative devices for gastroenterologic interventions. It has been acquired by an industrial group in 2016.

Visit Website

Biotech

Ongoing

Sector: Biotech

Employees: 5

Laboratory specialized in the identification of asbestos fibres presents in bulk samples and air samples.

Visit website

Investment Portfolio

9 companies

Investment Portfolio

18 companies

Fintech

Ongoing

Sector: Fintech

Employees: 14

A single platform for all your debt collection partners
Benchmark them, reduce costs and improve your net recovery rate

Visit Website

Medtech

Ongoing

Sector: Medtech

Employees: 50

Offers a Risk-Based Monitoring software to improve data quality, increase operational efficiency and reduce regulatory submission risk, in clinical studies runned by pharma companies, CRO, CTO, …

Visit website

Biotech

Ongoing